ATRA (Atara Biotherapeutics, Inc.) יחס שווי שוק לשווי בספרים

The Atara Biotherapeutics (ATRA) price chart allows for an assessment of the effectiveness of implementing automated bioreactors, which eliminate personnel errors during T-cell cultivation. The company is creating a unique environment of ready-made therapeutic solutions to combat cancer and the Epstein-Barr virus, reaching the level of -2.14. Meanwhile, Pascal Touchon's management is currently restructuring the operating model toward a partnership format, sparking cautious market interest.

Asset managers require an objective assessment of an issuer's overvaluation relative to its actual assets. This indicator compares the market value of the business with its net book value, revealing the extent of speculative price inflation. By analyzing the price-to-book ratio, an investor determines entry or exit points for the asset. For Atara Biotherapeutics (ATRA), this metric reflects the capitalization of intellectual capital and ESG strategies for bio-waste optimization. Effective management of environmental risks and bioethics directly impacts the fundamental value of the company.